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INTRODUCTION
The gonadal steroid hormone estro-
gen (i.e., estradiol) seems to modulate
higher order cognitive processes driven by
dopamine (DA) such as learning, reward
processing, working memory (WM), and
inhibitory control (Hampson, 1990a,b;
Maki et al., 2002; Caldu and Dreher,
2007; Dreher et al., 2007; Gasbarri et al.,
2008; Colzato et al., 2010, 2012; Jacobs
and D’Esposito, 2011). However, it is
important to note that sex steroid hor-
mones have been shown to impact several
other neurotransmitter systems, includ-
ing gamma-aminobutyric acid (GABA).
Indeed, in healthy women the cortical
GABA levels declines from the follic-
ular phase (FP) to the mid luteal and
late luteal phases (Epperson et al., 2002).
In a recent review, Sinclair et al. (2014)
suggested that the adolescent brain is
shaped by the interaction between estro-
gen and glucocorticoids with a specific
impact on DA neurotransmission. The
focus of the present opinion article is not
on glucocorticoid-estrogen interactions
but on estrogen effects on higher-
order cognition in unstressed human
females.
High levels of estradiol are accompa-
nied by increases in the attentional blink
(Hollander et al., 2005) and in interference
in the Stroop color-word task (Hatta and
Nagaya, 2009), indicating reduced cogni-
tive control. Moreover, the reactivity of
the reward system is augmented in women
during themidfollicular phase when estro-
gen is unopposed by progesterone (Dreher
et al., 2007).
Previous studies have shown that gen-
der differences in DA-modulated higher-
order cognitive processes are restricted to
a particular phase of the female menstrual
cycle: the late FP, in which the estrogen
level is high. Growing evidence suggests
that the dopaminergic system seems to be
particularly strongly affected by estrogen.
After estrogen enters the brain, it is con-
verted into cathecol estrogen, which has
been considered to inhibit the catechol O-
methyltransferase (Ball et al., 1972), an
enzyme responsible for the degradation
of DA in prefrontal cortex (PFC). Several
studies have pointed out that the estrous
cycle is related to augmentation in DA
release associated with high levels of estro-
gen in rodents (Di Paolo et al., 1986;
Becker et al., 2001; Dazzi et al., 2007; for
review see Becker, 1999) and in monkeys
(Czoty et al., 2009). Moreover, as pointed
out by Czoty et al. (2009), receptor autora-
diography studies have revealed that D2
receptor densities can raise in the pres-
ence of natural elevations in estrogen dur-
ing the estrous cycle and after exogenous
estrogen administration (Pazos et al., 1985;
Di Paolo et al., 1988; Bazzett and Becker,
1994; Becker, 1999; see Di Paolo, 1994).
Interestingly, the ventral tier of themid-
brain sends its DA projections to the dor-
sal and lateral parts of the PFC, while
the dorsal tier sends its DA projections
primarily to the ventral striatum, which
projects strongly to ventrolateral and ven-
tromedial PFC (Cools, 2006). As suggested
by Miller (2000), reward information may
be mediated by the dopamine-mediated
innervation of PFC from a group of cells
situated in the midbrain ventral tegmental
area (VTA). Inhibitory control of behav-
ior and thoughts seems to be driven by
the frontal/basal-ganglia system. Finally,
DA levels in PFC are related to the
maintenance of WM information (Cools,
2006). Given these links between estro-
gen, DA, and PFC, it should not be sur-
prising that PFC-depending functions, like
inhibitory control, WM, and reward pro-
cessing, are particularly affected by the
menstrual cycle.
INDIVIDUAL BASELINE LEVELS OF DA
MAY EXHIBIT DIFFERENTIAL
SENSITIVITY TO ESTROGEN
In some previous studies, estrogen seems
to have modulated cognitive processes in
opposite directions or in unreliable ways.
For example, studies have found improved
verbal working memory (Rosenberg and
Park, 2002) and better performance on
a test of implicit memory (Maki et al.,
2002) when the estrogen level was high,
while others found high levels of estro-
gen to have a negative effect on delayed
matching-to-sample working memory
task (Gasbarri et al., 2008). Jacobs and
D’Esposito (2011) were the first to sug-
gest that inconsistencies in the literature
linking WM and estrogen (Maki et al.,
2002; Rosenberg and Park, 2002; Gasbarri
et al., 2008) may be explained by taking
baseline levels of DA into account. Indeed,
these authors showed that the direction of
the effect estrogen has on WM depends
on indices of baseline DA (as assessed by
the genetic variability associated with the
COMT Val158Met genotype).
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We suggest that not only for WM,
but for all cognitive processes related to
DA, the effect of estrogen might depend
on individual variation in baseline DA
function, which follows an “Inverted-U”-
shaped function. Indeed, neurotransmit-
ters such as DA often relate to performance
in a nonlinear fashion, with the best per-
formance related to a medium level, while
higher levels are likely to be counterpro-
ductive (Muly et al., 1998; Goldman-Rakic
et al., 2000). This effect is explained by the
existence of GABAergic interneurons with
D1 receptors and inhibitory input to cor-
tical pyramidal cells, which are related to
cognitive performance. At moderate levels
of dopamine release the function of these
pyramidal cells (but not of the interneu-
rons) is enhanced, which leads to better
performance as compared to lower levels.
But at high levels of dopamine release, the
GABAergic inhibitory interneurons also
get excited and start projecting the neu-
rotransmitter GABA onto the pyramidal
cortical cells. This provides them with
inhibitory input, leading to impaired per-
formance (Goldman-Rakic et al., 2000).
Consistent with this picture, the impact of
most dopaminergic agonist drugs is mod-
ulated by individual differences: increas-
ing the dopamine level is likely to be
beneficial for individuals whose level
falls short of the optimal level but to
impair the performance of individuals
with medium (optimal) or high levels
(Cools, 2006).
We speculate that different individu-
als may have different baseline levels of
DA and may therefore exhibit differen-
tial sensitivity to the positive and negative
effects of estrogen. Given that estrogen is
associated with higher DA turnover rates,
if estrogen affects the DA functioning in
driving a particular cognitive function, we
would expect a cognitive beneficial effect
in the late FP (i.e., with the highest level
of estrogen) for individuals with a low DA
baseline level. In contrast, we would expect
a cognitive detrimental effect in the late
FP for individuals with an already optimal
baseline level. That is, low baseline levels
of DA, which are in general accompanied
by poor cognitive performance, may be
improved by high levels of estrogen. In
contrast, high baseline levels of DA, com-
monly related to good cognitive perfor-
mance, may be impaired by estrogen.
Colzato and colleagues showed, in
two independent samples, that late FP
was associated with both less efficient
inhibitory output control (Colzato et al.,
2010) and more efficient inhibitory input
control (Colzato et al., 2012). Of course,
we cannot exclude that this dissociation
simply reflected the independence of input
and output control (Johnston et al., 1995).
However, if our idea that the effect of
estrogen on all DA-driven cognitive pro-
cesses depends on individual variation in
baseline DA is correct, it is a real possibil-
ity that individual differences have mod-
ulated our previous findings. If so, it is
reasonable to assume that our first study
(Colzato et al., 2010) tapped a sample with
an already optimal DA baseline level while
the second (Colzato et al., 2012) happened
to assess a sample with low DA baseline
levels.
MARKERS OF DA BASE LEVELS
The direct assessment of DA function
in humans is only possible by means of
positron emission tomography (PET) so
far, which is, however, very expensive and
highly invasive due to radioactive con-
tamination and arterial blood sampling
(Volkow et al., 2009). An ideal index of
DA base levels, also used by Jacobs and
D’Esposito (2011), is genetic variability
related to levels of DA, which is nonethe-
less still a costly procedure.
Interestingly, DA can be found in
high concentration in the amacrine and
interplexiform cells of the retina (Bodis-
Wollner and Tzelepi, 1998; Witkovsky,
2004). Abnormal color discrimination has
been reported for several neuropsychiatric
conditions underlying al dopaminer-
gic functions, such as Parkinson’s and
Huntington’s disease, Tourette syndrome,
ADHD, and cocaine use (Paulus et al.,
1993; Pieri et al., 2000; Melun et al., 2001;
Tannock et al., 2006; Hulka et al., 2013).
Roy et al. (2003) suggested that color
vision impairment points to a central
hypodopaminergic state. Very recently,
color vision has been found to predict the
efficiency in resolving response conflict
given that both are driven by dopamine
(Colzato et al., under revision). This
raises the possibility that individual color
discrimination performance predicts indi-
vidual differences in sensitivity to the
positive (i.e., enhancing) and negative
(i.e., unfavorable) effects of estrogen. For
example in tasks assessing cognitive con-
trol and adaptation one would expect
benefits (e.g., better goal regulation in the
face of response conflict) in the late FP for
individuals with poor color discrimination
but a detrimental effect (e.g., poorer goal
regulation) in individuals with optimal
color discrimination.
Another interesting measure of DA
functioning is the spontaneous eyeblink
rate (EBR), a well-established clinical
indicator (Karson, 1983; Shukla, 1985;
Blin et al., 1990; Taylor et al., 1999).
Patients with DA-related dysfunction show
atypical patterns: EBRs are elevated in
in schizophrenia patients (Freed, 1980)
but reduced in recreational cocaine users
(Colzato et al., 2008b) and Parkinson’s
patients (Deuschel and Goddemeier,
1998). Moreover, pharmacological stud-
ies in nonhuman primates and humans
have shown that DA agonists, such as apo-
morphine, and antagonists increase and
decrease EBRs, respectively, (Blin et al.,
1990; Kleven and Koek, 1996). Similarly
to color vision, EBR has also been found
to predict DA-driven cognitive processes
(e.g., Dreisbach et al., 2005; Colzato et al.,
2007, 2008a, 2009). Accordingly, EBR, in
interaction with the individual genetic
setup, should predict individual differ-
ences in sensitivity to the positive and
negative effects of estrogen. In particu-
lar, we would expect cognitive benefits in
the late FP for individuals with low EBR
but impairments in individuals with an
average/high EBR.
It might be particularly informative
to use proton magnetic resonance spec-
troscopy (1H-MRS) and plasma levels of
homovanillic acid (HVA) to trace the
impact of estrogen on the DA system.
1H-MRS permits to measure the con-
centration of particular chemicals, based
on subtle differences in the resonance
of the protons they contain. This tech-
nique has been successfully applied in the
past to reflect changes in dopamine path-
ways (Moore et al., 2006) and to investi-
gate the effect of dopaminergic treatment
on the cortex (Lucetti et al., 2007). In
contrast to PET, 1H-MRS does not use
invasive radioactive tracers and it is way
less expensive. 1H-MRS allows measur-
ing brain metabolites including creatine
(Cr), inositol (Ino), and glutamate and
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glutamine (Glx), and the ratio between
them. Because protons experience differ-
ent shielding effects from the surrounding
electrons in different molecules, their res-
onance varies from one type of molecule
to another. In the late FP we would expect
increased brain DA and, accordingly, a
modulation of the Glx-to-Cr and Glx-to-
Ino ratio.
Homovanillic acid (HVA) is a metabo-
lite of DA which is typically decreased
in repetitive behavior disorders (Lewis
et al., 1996) and it may be altered in in
disorders of catecholamine metabolism.
For example, monamine oxidase-A defi-
ciency can cause decreased HVA val-
ues, while a deficiency of dopamine
beta-hydrolase (the enzyme that converts
dopamine to norepinephrine) can cause
elevatedHVA concentrations. Accordingly,
HVA values should predict individual dif-
ferences in sensitivity to the positive and
negative effects of estrogen. In partic-
ular, we would expect cognitive bene-
fits in the late FP for individuals with
low HVA values but impairments in
individuals with an average/high HVA
values.
SUMMARY
We propose that future studies inves-
tigating the effect of estrogen on DA-
driven higher order cognitive processes
should take into account individual dif-
ferences in DA base levels. The existing
research on the role of estrogen in higher
order cognitive processes has been mainly
“effect”-driven, and thus only shown
that estrogen can have an effect without
explaining how it modulates cognitive pro-
cesses and why some people benefit more
than others. To get a better understand-
ing of the underlying mechanism and the
interplay between estrogen, dopaminer-
gic supply, and cognitive functioning it is
mandatory to develop a comprehensive,
detailed model of how estrogen modulates
higher order cognitive processes in healthy
humans.
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